A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT05221840. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Double-blind, Placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase III, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) or durvalumab (MEDI4736) with monalizumab (IPH2201) in adults with locally advanced (Stage III), unresectable NSCLC, who have not progressed following platinum-based cCRT.
Study identification
- NCT ID
- NCT05221840
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,051 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 7, 2022 (Actual)
- Primary completion
- Sep 30, 2026 (Estimated)
- Completion
- Jul 2, 2030 (Estimated)
- Last update posted
- Jun 18, 2026
2022 – 2030
United States locations
- U.S. sites
- 33
- U.S. states
- 21
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | San Diego | California | 92123 | — |
| Research Site | New Haven | Connecticut | 06510 | — |
| Research Site | Stuart | Florida | 34994 | — |
| Research Site | Urbana | Illinois | 61801 | — |
| Research Site | New Albany | Indiana | 47150 | — |
| Research Site | Lexington | Kentucky | 40503 | — |
| Research Site | Louisville | Kentucky | 40241 | — |
| Research Site | Annapolis | Maryland | 21401 | — |
| Research Site | Baltimore | Maryland | 21201 | — |
| Research Site | Baltimore | Maryland | 21229 | — |
| Research Site | Bethesda | Maryland | 20817 | — |
| Research Site | Grand Rapids | Michigan | 49503 | — |
| Research Site | Duluth | Minnesota | 55805 | — |
| Research Site | Billings | Montana | 59101 | — |
| Research Site | Ridgewood | New Jersey | 07450 | — |
| Research Site | Ithaca | New York | 14850 | — |
| Research Site | Greensboro | North Carolina | 27403 | — |
| Research Site | Cleveland | Ohio | 44124 | — |
| Research Site | Cleveland | Ohio | 44195 | — |
| Research Site | Maumee | Ohio | 43537 | — |
| Research Site | Portland | Oregon | 97239 | — |
| Research Site | Philadelphia | Pennsylvania | 19104 | — |
| Research Site | York | Pennsylvania | 17403 | — |
| Research Site | Sioux Falls | South Dakota | 57105 | — |
| Research Site | Houston | Texas | 77030 | — |
| Research Site | Charlottesville | Virginia | 22908 | — |
| Research Site | Fairfax | Virginia | 22031 | — |
| Research Site | Fredericksburg | Virginia | 22408 | — |
| Research Site | Richmond | Virginia | 23235 | — |
| Research Site | Richland | Washington | 99352 | — |
| Research Site | Spokane | Washington | 99204 | — |
| Research Site | Tacoma | Washington | 98405 | — |
| Research Site | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 169 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05221840, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 18, 2026 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05221840 live on ClinicalTrials.gov.